EPHA2 and central nervous system cancer: Ephrin type-A receptor 2 (EphA2) CAR T cells have been developed to target the EphA2+ U373 glioma xenograft mouse model and the results indicated that CARs with a short spacer had significantly greater antitumor activity, which could be augmented by transgenic expression of cytokines to counteract the immunosuppressive TME [82].